A detailed history of Neville Rodie & Shaw Inc transactions in Eli Lilly & CO stock. As of the latest transaction made, Neville Rodie & Shaw Inc holds 14,934 shares of LLY stock, worth $11.3 Million. This represents 0.97% of its overall portfolio holdings.

Number of Shares
14,934
Previous 15,373 2.86%
Holding current value
$11.3 Million
Previous $13.9 Million 4.95%
% of portfolio
0.97%
Previous 1.06%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 01, 2024

SELL
$772.14 - $960.02 $338,969 - $421,448
-439 Reduced 2.86%
14,934 $13.2 Million
Q2 2024

Jul 01, 2024

BUY
$724.87 - $909.04 $150,048 - $188,171
207 Added 1.36%
15,373 $13.9 Million
Q1 2024

Apr 09, 2024

BUY
$592.2 - $792.28 $424,015 - $567,272
716 Added 4.96%
15,166 $11.8 Million
Q4 2023

Jan 02, 2024

BUY
$525.19 - $619.13 $745,769 - $879,164
1,420 Added 10.9%
14,450 $8.42 Million
Q3 2023

Oct 10, 2023

BUY
$434.7 - $599.3 $199,962 - $275,678
460 Added 3.66%
13,030 $7 Million
Q2 2023

Jul 06, 2023

BUY
$350.74 - $468.98 $3.49 Million - $4.66 Million
9,940 Added 377.95%
12,570 $5.9 Million
Q1 2023

Apr 04, 2023

BUY
$310.63 - $364.82 $214,334 - $251,725
690 Added 35.57%
2,630 $903,000
Q4 2022

Jan 03, 2023

BUY
$321.55 - $374.67 $213,830 - $249,155
665 Added 52.16%
1,940 $710,000
Q3 2022

Oct 04, 2022

BUY
$296.48 - $337.87 $22,236 - $25,340
75 Added 6.25%
1,275 $412,000
Q4 2020

Mar 04, 2021

BUY
$130.46 - $172.63 $156,552 - $207,156
1,200 New
1,200 $203,000
Q3 2019

Oct 02, 2019

SELL
$106.79 - $116.16 $234,938 - $255,552
-2,200 Closed
0 $0
Q2 2019

Jul 01, 2019

SELL
$110.79 - $129.32 $3,656 - $4,267
-33 Reduced 1.48%
2,200 $244,000
Q1 2019

Apr 08, 2019

BUY
$111.31 - $131.02 $3,673 - $4,323
33 Added 1.5%
2,233 $290,000
Q3 2018

Oct 09, 2018

BUY
$85.86 - $107.31 $188,892 - $236,082
2,200 New
2,200 $236,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $717B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Neville Rodie & Shaw Inc Portfolio

Follow Neville Rodie & Shaw Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neville Rodie & Shaw Inc, based on Form 13F filings with the SEC.

News

Stay updated on Neville Rodie & Shaw Inc with notifications on news.